Observational studyHeart (British Cardiac Society)2016

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.

Simon G Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.